A new educational approach helps children with sickle cell disease complete MRI tests without sedation. Sitting still is tough for young children, making MRI scans a challenge. The scans require that patients remain motionless for extended periods. Findings from St. Jude Children's Research Hospital showed that a brief, targeted intervention dramatically increases the likelihood that children as young as 5 years old will be able to undergo testing without sedation.
Added by Peter Hofland, PhD on August 31, 2012 at 8:30am — No Comments
Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF) aiming to raise funds to hasten the pace of groundbreaking translational research in cancer, earlier today announced that Hollywood is once again rallying together and lending its support to the third SU2C primetime television fundraising special. The event will air simultaneously on all major networks in the United States, on Friday, September…Continue
Added by Peter Hofland, PhD on August 22, 2012 at 5:30am — No Comments
The National Breast Cancer Foundation, Inc.® (NBCF) earlier today announced the official launch of its Early Detection Plan (EDP), a new free iPhone app designed to encourage women to become more proactive about their health by scheduling reminders via push notifications to perform routine breast self-exams and schedule clinical…Continue
Added by Peter Hofland, PhD on August 21, 2012 at 5:00pm — No Comments
Reovirus (Reolysin®; Oncolytics Biotech, Calgary, AB, Canada), a proprietary variant of the Respiratory Enteric Orphan Virus, is a benign, double-stranded RNA human virus with oncolytic properties. In a variety of clinical trials, the virus has shown to selectively kill tumor cells with activated signaling through the RAS pathway.
The RAS protein family members belong to a class of protein called…Continue
Added by Peter Hofland, PhD on August 16, 2012 at 5:30am — No Comments
Stress can promote breast cancer cell colonization of bones, Vanderbilt Center for Bone Biology investigators have discovered. The preclinical studies, reported on July 17 in PLoS Biology, demonstrate that activation of the sympathetic nervous system, which is active in response to stress, primes the bone environment for breast cancer cell metastasis.
In addition, the…Continue
Added by Peter Hofland, PhD on August 9, 2012 at 2:00pm — No Comments
Men diagnosed with prostate cancer are less likely to die from the disease than from largely preventable conditions such as heart disease. A new study from Harvard School of Public Health which looks at causes of death among men with prostate cancer suggests that encouraging healthy lifestyle changes should play an important role in prostate cancer management.
Mara Epstein, a postdoctoral…Continue
Added by Peter Hofland, PhD on August 9, 2012 at 1:30pm — No Comments
Inhibitors of indoleamine 2,3-dioxygenase (IDO), a tryptophan-catabolizing enzyme that induces immune tolerance, are being assessed in clinical trials as a potential treatment for recurrent or refractory solid tumors. Clear genetic rationale for these trials, together with evidence that primary and metastatic lung tumors might be particularly susceptible to the drugs, is now reported in a preclinical study published in…Continue
Added by Peter Hofland, PhD on August 8, 2012 at 4:00pm — No Comments
Early in July, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product decitabine (Dacogen®), Janssen-Cilag), 50 mg, powder for concentrate for solution for infusion, intended for the treatment of acute myeloid leukemia…Continue
Added by Peter Hofland, PhD on August 7, 2012 at 5:00pm — No Comments
The U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept, Sanofi and Regeneron Pharmaceuticals, Inc) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
"Colorectal cancer is one of the deadliest cancers and is responsible for more than half a million deaths…Continue
Added by Peter Hofland, PhD on August 3, 2012 at 1:30pm — No Comments
More than 4 million people in the European Union are affected by rare cancers. Rare diseases are generally defines as diseases with a prevalence of less than 50 patients per 100,000 people per year. A more conservative definition, which takes a number of particularities of natural history and prognosis into account (including the incidence of a cancers with less than 5 patients per 100,000 people per year), suggests that rare cancers represent about 22% of all malignant neoplasm…Continue
Added by Peter Hofland, PhD on August 1, 2012 at 12:30pm — No Comments